

TAVI Forum 14

Friday, April 17, 2026

Hyperion Hotel Munich
Truderinger Str. 13, 81677
München, Germany

Agenda

1:00 PM	Registration and Lunch	
2:00 PM	Introductory Remarks	
	<p><i>Welcome and Introductions</i></p>	<p>Shilpa Mitra, Forum for Collaborative Research Veronica Miller, Forum for Collaborative Research Per Ljungman, Karolinska Institutet Camille Kotton, Massachusetts General Hospital</p>
2:15 PM	Session I: Adenovirus Updates	
2:15 PM	ADENOCLEAR Study: Preliminary Results	Jérôme Le Goff, Université Paris Cité
2:30 PM	Brincidofovir Phase 3 Study Against AdV: ENOVIA Launched	Nkechi Azie, Symbio Pharmaceuticals Ltd
2:40 PM	Discussion	All
2:50 PM	Session II: CMV Updates	
2:50 PM	Cytogam in the Modern Era: Investigator-Initiated Study Updates	Winston Ally, Kamada Ltd.
3:00 PM	CMV CMI in Hematopoietic Cell Transplant	Guy Handley, UT MD Anderson Cancer Center*
3:10 PM	CMV CMI in Solid Organ Transplant	Cesar Berto, University of Alabama at Birmingham*
3:20 PM	Discussion	All
3:30 PM	Session III: BK Polyomavirus Updates	
3:30 PM	AIC468: A first-in-class antiviral antisense oligonucleotide in clinical development for the treatment of BKV in kidney transplant recipients	Peter Lischka, AiCuris Anti-Infective Cures AG
3:40 PM	VP1-Targeting Small Molecules for BK Polyomavirus: Toward Direct-Acting Antivirals with Cross-Polyomavirus Activity	Ali Munawar, Orthogon Therapeutics LLC
3:50 PM	Potravitug	Juergen Beck, Memo Therapeutics AG*
4:00 PM	TAVI Forum BK Project Update: Leuven/Roche	Maarten Naesens, Leuven University Hospital*
4:10 PM	Discussion	All
4:20 PM	Break	
4:35 PM	Session IV: Herpes Viruses Updates	
4:35 PM	Pritelivir, Novel Helicase Primase Inhibitor, Phase 3 Trial Results	Genovefa Papanicolaou, Memorial Sloan Kettering Cancer Center
4:50 PM	Pritelivir, Novel Helicase Primase Inhibitor, for the treatment of refractory HSV infection: NDA Progress & Pathway to Launch	Cynthia Wat, AiCuris Anti-Infective Cures AG
5:00 PM	Gilead's HSV Program	Yoshihiko Murata, Gilead Sciences Inc.
5:10 PM	Kaposi Sarcoma-Associated Herpesvirus (HHV-8) Infection in Solid Organ Transplant Recipients: State of the Art and Open Challenges	Alessandra Mularoni, ISMETT
5:25 PM	TAVI Forum HHV-6 Project Update	Per Ljungman, Karolinska Institutet
5:35 PM	Discussion	All
5:50 PM	Session V: New Topics in Transplant & Immunocompromised Populations	
5:50 PM	Tabelecleucel, an allogeneic cell therapy for EBV+ PTL: Clinical Program Update	Ruchit Parikh, Pierre-Fabre Pharmaceuticals*
6:00 PM	VMS063: a novel, highly potent, half-life extended, pan-measles variant antibody	Robert Allen, Invivyd Inc.
6:10 PM	MSD's Respiratory Virus Programs	Michael Wong, Merck & Co
6:20 PM	The Urgent Need for Therapeutic Innovation in Kidney Transplantation	Kevin Fowler, The Voice of the Patient*
6:35 PM	Discussion	All
6:45 PM	Concluding Remarks	
	<p><i>Next Steps</i></p>	<p>Veronica Miller, Forum for Collaborative Research Per Ljungman, Karolinska Institutet Camille Kotton, Massachusetts General Hospital</p>
7:00 PM	Meeting Adjourn & Reception	

* Indicates remote participation